Skip to main content

Table 2 Infused ADV-VST characteristics

From: Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial

Patient

ADV-VST origin

Donor ADV response (SFCs per 106 PBMC)

VST dose (×103 viables CD3+ IFNγ+/kg)

VST dose (×103 CD4+ IFNγ+/kg) [enrichment (% of CD4)]

VST dose (×103 CD8+ IFNγ+/kg) [enrichment (% of CD8)]

01-01

HSC donor

96

0.39

0.35 [68.4]

0.04 [7.1]

07-03

HSC donor

527

28.10

26.0 [78.5]

2.10 [15.8]

09-04

HSC donor

177

0.25

0.12 [51.0]

0.13 [45.9]

06-05

HSC donor

UN

0.92

0.34 [47.6]

0.58 [56.6]

07-06

Haplo donor (mother)

UN

1.21

0.66 [15.1]

0.55 [11.7]

02-08

Haplo donor (mother)

364

1.10

0.60 [87.7]

0.50 [76.4]

11-10

Haplo donor (sister)

446

3.90

2.99 [96.0]

0.90 [93.5]

12-11

Haplo donor (mother)

370

9.14

8.13 [94.3]

1.01 [90.6]

08-12

Haplo donor (mother)

561

8.28

7.31 [84.5]

0.98 [69.6]

01-13

HSC donor

271

1.41

1.34 [81.9]

0.08 [39.8]

12-14

Haplo donor (mother)

492

9.38

7.70 [96.1]

1.61 [88.2]

Mean

 

367

5.83

5.05 [72.8]

0.77 [54.1]

SD

 

160

8.23

7.66 [25.5]

0.65 [32.5]

  1. ADV-VST adenovirus-specific T cells, SFC secretion-forming cells, PBMC peripheral blood mononuclear cells, Haplo donor haploidentical donor, SD standard deviation, UN unavailable